Sugi Predict

Sugi Predict / Compounds / SCHEMBL1962644

SCHEMBL1962644

SCHEMBL1962644

C[C@@]12CCC[C@H]1[C@@H]1CC[C@H]3CC(=O)CC[C@]3(C)[C@H]1CC2

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AKR1B10 O60218 3/20 0.65
▸ AKR1B1 P15121 3/20 0.65
▸ CYP19A1 P11511 2/20 0.65
▸ OR51E2 Q9H255 1/20 0.65
▸ SHBG P04278 3/20 0.64
▸ GPBAR1 Q8TDU6 2/20 0.64
▸ NR3C1 P04150 1/20 0.64
▸ PGR P06401 1/20 0.64
▸ SERPINA6 P08185 1/20 0.64
▸ NR3C2 P08235 1/20 0.64
▸ CYP3A4 P08684 1/20 0.64
▸ AR P10275 1/20 0.64
▸ HSD17B10 Q99714 1/20 0.64
▸ MGAM O43451 1/20 0.64
▸ POLB P06746 1/20 0.62
▸ MAPK1 P28482 1/20 0.62
▸ KDM4E B2RXH2 1/20 0.60
▸ MAPT P10636 1/20 0.60
▸ MEN1 O00255 1/20 0.58
▸ KMT2A Q03164 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9541973 1.00 AKR1B10 (0.65) AKR1B10AKR1B1CYP19A1OR51E2SHBG
SCHEMBL1427282 1.00 AKR1B10 (0.65) AKR1B10AKR1B1CYP19A1OR51E2SHBG
SCHEMBL27607786 1.00 AKR1B10 (0.65) AKR1B10AKR1B1CYP19A1OR51E2SHBG
SCHEMBL4572602 1.00 AKR1B10 (0.65) AKR1B10AKR1B1CYP19A1OR51E2SHBG
SCHEMBL27248784 1.00 AKR1B10 (0.65) AKR1B10AKR1B1CYP19A1OR51E2SHBG
SCHEMBL1651202 1.00 AKR1B10 (0.65) AKR1B10AKR1B1CYP19A1OR51E2SHBG
SCHEMBL24151978 1.00 AKR1B10 (0.65) AKR1B10AKR1B1CYP19A1OR51E2SHBG
SCHEMBL19877200 1.00 AKR1B10 (0.65) AKR1B10AKR1B1CYP19A1OR51E2SHBG
Propionic Acid SCHEMBL12694801 0.91 GPBAR1 (0.57) AKR1B10AKR1B1CYP19A1OR51E2SHBG
Stanolone SCHEMBL11325499 0.91 SHBG (0.82) AKR1B10AKR1B1CYP19A1OR51E2SHBG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220193095-A9 PHARMACEUTICAL COMPOSITIONS Shenzhen Pharmacin Co., Ltd. (CN) 2022-06-23 — — US claimed
EP-3914234-A1 PHARMACEUTICAL COMPOSITIONS Shenzhen Pharmacin Co., Ltd. (CN) 2021-12-01 — — EP claimed
WO-2020151633-A1 PHARMACEUTICAL COMPOSITIONS Shenzhen Pharmacin Co., Ltd. (CN) 2020-07-30 — — WO claimed
US-20200237784-A1 PHARMACEUTICAL COMPOSITIONS SHENZHEN PHARMACIN CO LTD (CN) 2020-07-30 — — US claimed
US-20120285076-A1 BED BUG ATTRACTANTS AND METHODS FOR TRAPPING BED BUGS SPRINGSTAR INC. (US) 2012-11-15 — — US claimed
US-20090124587-A1 METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS AUERBACH ALAN H 2009-05-14 — — US claimed
WO-2009009132-A1 USE OF 17ALPHA-HYDROXYLASE/C17, 20-LYASE INHIBITORS FOR THE TREATMENT OF CANCER COUGAR BIOTECHNOLOGY, INC. (US) 2009-01-15 — — WO claimed
JP-4230695-A — — None — — JP disclosed
WO-2025231149-A1 METHOD AND SYSTEM FOR EVALUATION AND DIAGNOSIS OF OLFACTORY CAPACITY IN HUMANS CONCORD FRAGRANCES LLC (US) 2025-11-06 — — WO disclosed
US-20240374617-A1 METHODS OF ACTIVATING MICROGLIAL CELLS UNIV NEW YORK STATE RES FOUND (US) 2024-11-14 — — US disclosed
US-11739066-B2 Method for fluoroalkylation of enamines ARXADA AG (CH) 2023-08-29 — — US disclosed
US-11739066-B2 Method for fluoroalkylation of enamines ARXADA AG (CH) 2023-08-29 — — US disclosed
US-20220204464-A1 Method for Fluoroalkylation of Enamines LONZA LTD (CH) 2022-06-30 — — US disclosed
EP-0375349-A1 Phosphinic acid substituted steroids as inhibitors of steroid 5alpha-reductase SMITHKLINE BEECHAM CORPORATION (US) 1990-06-27 — — EP disclosed
EP-0314199-A1 17 Beta-substituted-4-aza-5 alpha-androstenones and their use as 5 alpha-reductase inhibitors MERCK & CO. INC. (US) 1989-05-03 — — EP disclosed
US-4732897-A 4-AZA-17-BETA-SUBSTITUTED-5-ALPHA ANDROSTAN-3-ONES FARMITALIA CARLO ERBA, S.P.A. (IT) 1988-03-22 — — US disclosed
US-4732897-A 4-AZA-17-BETA-SUBSTITUTED-5-ALPHA ANDROSTAN-3-ONES FARMITALIA CARLO ERBA, S.P.A. (IT) 1988-03-22 — — US disclosed
EP-0200859-A1 Steroidal 5-alpha-reductase inhibitors, processes for their preparation and pharmaceutical compositions containing them FARMITALIA CARLO ERBA S.p.A. (IT) 1986-11-12 — — EP disclosed
US-4456601-A ANTIINFLAMMATORY, ANTIPYRETICS AGENTS RICHTER GEDEON VEGYESZETI GYAR RT. (HU) 1984-06-26 — — US disclosed
US-4071625-A 19-Oxygenated-5α-androstanes for the enhancement of libido RICHARDSON-MERRELL INC. (US) 1978-01-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090124587-A1 METHODS FOR TREATING CANCER USING 17alpha-HYDROXYLASE/C17,20-LYASE INHIBITORS CYP17A1, CYP21A2, HSD17B11 AKR1B10 44/4885AKR1B1 24/4885CYP19A1 12/4885
US-20220193095-A9 PHARMACEUTICAL COMPOSITIONS LIPA, LIPC, MGLL AKR1B10 742/4885AKR1B1 941/4885CYP19A1 674/4885
US-20240374617-A1 METHODS OF ACTIVATING MICROGLIAL CELLS INPP5B, PPIP5K2, PLA2G4B AKR1B10 4662/4885AKR1B1 4615/4885CYP19A1 4849/4885
US-20200237784-A1 PHARMACEUTICAL COMPOSITIONS LIPA, LIPC, MGLL AKR1B10 742/4885AKR1B1 941/4885CYP19A1 674/4885
US-11739066-B2 Method for fluoroalkylation of enamines HNMT, PNMT, INMT AKR1B10 773/4885AKR1B1 1657/4885CYP19A1 3595/4885
US-20220204464-A1 Method for Fluoroalkylation of Enamines HNMT, PNMT, INMT AKR1B10 773/4885AKR1B1 1657/4885CYP19A1 3595/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.